HK1025040A1 - Stable liquid interferon formulations. - Google Patents

Stable liquid interferon formulations.

Info

Publication number
HK1025040A1
HK1025040A1 HK00102221A HK00102221A HK1025040A1 HK 1025040 A1 HK1025040 A1 HK 1025040A1 HK 00102221 A HK00102221 A HK 00102221A HK 00102221 A HK00102221 A HK 00102221A HK 1025040 A1 HK1025040 A1 HK 1025040A1
Authority
HK
Hong Kong
Prior art keywords
liquid
interferon
compositions
beta
stable liquid
Prior art date
Application number
HK00102221A
Other languages
English (en)
Inventor
Mary D Dibiasi
Mark Staples
Wen-Li Chung
Eric Scharin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1025040(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of HK1025040A1 publication Critical patent/HK1025040A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK00102221A 1996-12-24 2000-04-12 Stable liquid interferon formulations. HK1025040A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24
PCT/US1997/023817 WO1998028007A1 (en) 1996-12-24 1997-12-23 Stable liquid interferon formulations

Publications (1)

Publication Number Publication Date
HK1025040A1 true HK1025040A1 (en) 2000-11-03

Family

ID=21875893

Family Applications (2)

Application Number Title Priority Date Filing Date
HK00102221A HK1025040A1 (en) 1996-12-24 2000-04-12 Stable liquid interferon formulations.
HK06108948.0A HK1092048A1 (en) 1996-12-24 2006-08-11 Stable liquid interferon formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK06108948.0A HK1092048A1 (en) 1996-12-24 2006-08-11 Stable liquid interferon formulations

Country Status (28)

Country Link
EP (1) EP0948358B2 (ja)
JP (5) JP4878664B2 (ja)
KR (2) KR20000069664A (ja)
CN (2) CN1733296B (ja)
AT (1) ATE270899T1 (ja)
AU (1) AU738362B2 (ja)
BG (2) BG65418B1 (ja)
BR (1) BR9714434A (ja)
CA (1) CA2275890C (ja)
CZ (1) CZ300636B6 (ja)
DE (1) DE69729880T3 (ja)
DK (1) DK0948358T4 (ja)
EA (1) EA002754B1 (ja)
EE (2) EE04266B1 (ja)
ES (1) ES2224290T5 (ja)
HK (2) HK1025040A1 (ja)
HU (1) HU224222B1 (ja)
IL (1) IL130524A (ja)
IS (1) IS2070B (ja)
MX (1) MX337876B (ja)
NO (1) NO327844B1 (ja)
NZ (2) NZ336548A (ja)
PL (1) PL193447B1 (ja)
PT (1) PT948358E (ja)
SI (1) SI0948358T2 (ja)
SK (1) SK284989B6 (ja)
TR (1) TR199901968T2 (ja)
WO (1) WO1998028007A1 (ja)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2275890C (en) * 1996-12-24 2011-11-01 Biogen, Inc. Stable liquid interferon formulations
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6923956B1 (en) 1997-09-23 2005-08-02 Rentschler Biotechnologie Gmbh Liquid interferon-β formulations
ES2408784T3 (es) * 1999-05-31 2013-06-21 Mitsubishi Chemical Corporation Preparaciones liofilizadas de HGF
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
WO2003061687A1 (en) * 2002-01-18 2003-07-31 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
ES2523655T5 (es) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
RU2364609C2 (ru) 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
CN102872451A (zh) 2003-08-14 2013-01-16 诺和诺德医疗保健公司 因子vii多肽类的含水液体药物组合物
CN100548228C (zh) * 2003-11-13 2009-10-14 阿尔扎公司 用于透皮递送的组合物和装置
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
RU2373953C2 (ru) 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Стабилизированная композиция, содержащая полипептид фактора vii
CA2567309A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
EP1800689B1 (en) * 2004-08-24 2016-12-28 Daiichi Sankyo Company, Limited Liquid preparation of physiologically active peptide
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
BRPI0517697A (pt) 2004-11-10 2008-10-14 Chiron Corp interferon-beta deamidado
CN101102739B (zh) * 2005-01-12 2017-02-08 比奥根Ma公司 运输干扰素‑β的方法
AU2006206272A1 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
EP2264161A1 (en) 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
US8277845B2 (en) * 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby
EP2234645B1 (en) 2007-12-20 2012-05-02 Merck Serono S.A. Peg-interferon-beta formulations
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2283027B2 (en) 2008-05-01 2018-04-18 Arecor Limited Protein formulation
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
ES2716088T3 (es) 2010-02-04 2019-06-10 Csl Behring Ag Preparado de inmunoglobulina
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012077696A1 (ja) * 2010-12-09 2012-06-14 丸石製薬株式会社 アセトアミノフェンの安定化剤
CN103702680A (zh) 2011-03-15 2014-04-02 比金戴克股份有限公司 采用快速滴定递增剂量方案用于降低与肌肉内施用干扰素有关的流感样症状的方法
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CA2864740A1 (en) * 2012-04-19 2013-10-24 C.R. Bard, Inc. Infusates with enhanced ph stability under ethylene oxide sterilization
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) * 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程（集团）股份有限公司 一种重组人干扰素α2b制剂
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
MA49947B1 (fr) 2017-08-22 2023-03-31 Biogen Ma Inc Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
KR20210009982A (ko) * 2019-07-18 2021-01-27 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
US20230159605A1 (en) * 2020-04-29 2023-05-25 Abion Inc. Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
US20230210857A1 (en) * 2021-12-27 2023-07-06 Enalare Therapeutics Inc. Respiratory stimulant parenteral formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
TW249202B (ja) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
EP0752880A4 (en) * 1994-04-08 2000-08-09 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASES BY ORAL TOLERATION AND / OR INTERFERON OF TYPE I
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
CA2275890C (en) * 1996-12-24 2011-11-01 Biogen, Inc. Stable liquid interferon formulations

Also Published As

Publication number Publication date
NZ512792A (en) 2002-11-26
JP5851695B2 (ja) 2016-02-03
AU738362B2 (en) 2001-09-13
EE9900313A (et) 2000-04-17
SI0948358T2 (sl) 2012-03-30
EP0948358B1 (en) 2004-07-14
SK284989B6 (sk) 2006-04-06
KR101042660B1 (ko) 2011-06-20
EP0948358B2 (en) 2011-11-23
JP2012006979A (ja) 2012-01-12
BR9714434A (pt) 2000-05-02
NO327844B1 (no) 2009-10-05
HUP0000829A3 (en) 2002-01-28
JP4878664B2 (ja) 2012-02-15
CZ300636B6 (cs) 2009-07-08
PT948358E (pt) 2004-10-29
DK0948358T4 (da) 2012-03-19
DE69729880T3 (de) 2012-05-10
CN1245434A (zh) 2000-02-23
CN1222315C (zh) 2005-10-12
EE04266B1 (et) 2004-04-15
IS5087A (is) 1999-06-21
KR20070052363A (ko) 2007-05-21
IL130524A0 (en) 2000-06-01
EE200300127A (et) 2003-06-16
ES2224290T5 (es) 2012-03-12
JP2007204501A (ja) 2007-08-16
DK0948358T3 (da) 2004-11-08
EA199900597A1 (ru) 2000-02-28
SK85899A3 (en) 2000-01-18
CN1733296A (zh) 2006-02-15
BG109523A (en) 2007-05-31
NZ336548A (en) 2001-09-28
PL193447B1 (pl) 2007-02-28
NO993121L (no) 1999-08-24
CZ228299A3 (cs) 1999-12-15
JP2014098029A (ja) 2014-05-29
AU5619198A (en) 1998-07-17
JP2011068694A (ja) 2011-04-07
IL130524A (en) 2005-08-31
CN1733296B (zh) 2010-05-26
NO993121D0 (no) 1999-06-23
CA2275890A1 (en) 1998-07-02
WO1998028007A1 (en) 1998-07-02
JP2001519770A (ja) 2001-10-23
BG65418B1 (bg) 2008-07-31
MX337876B (es) 2016-03-22
HK1092048A1 (en) 2007-02-02
BG103594A (en) 2000-04-28
KR20000069664A (ko) 2000-11-25
HU224222B1 (hu) 2005-06-28
IS2070B (is) 2005-12-15
ATE270899T1 (de) 2004-07-15
EE04223B1 (et) 2004-02-16
PL334365A1 (en) 2000-02-28
BG65171B1 (bg) 2007-05-31
EP0948358A1 (en) 1999-10-13
DE69729880D1 (de) 2004-08-19
DE69729880T2 (de) 2005-07-07
TR199901968T2 (xx) 1999-12-21
HUP0000829A2 (en) 2000-07-28
ES2224290T3 (es) 2005-03-01
SI0948358T1 (en) 2005-04-30
CA2275890C (en) 2011-11-01
EA002754B1 (ru) 2002-08-29

Similar Documents

Publication Publication Date Title
HK1092048A1 (en) Stable liquid interferon formulations
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
CA2032499A1 (en) Polypeptide derivatives
AU6340686A (en) Pharmaceutical and dietary composition
CA2203033A1 (en) Compounds and compositions for delivering active agents
GR3024632T3 (en) Sustained-release protein formulations.
EP2145897A3 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
EP1077070A3 (en) Oral drug delivery compositions
TW364850B (en) Nematocidal compositions
AR244544A1 (es) Composicion desodorante.
AU4009789A (en) Recombinant natural killer cell activator
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
EP0161007A3 (en) Retro - inverso c-terminal hexapeptide analogues of substance p
AU678421B2 (en) Highly concentrated TCF pharmaceutical preparations
AU3494093A (en) S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
JPS57128662A (en) Amino acid mixture composition

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20171222